nach oben

The European Journal of Health Economics

Erschienen in:

01.06.2007 | Discussion

Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen

verfasst von: Livio Garattini

Erschienen in: The European Journal of Health Economics | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Excerpt

Following Cohen’s interesting criticism of our editorial, we shall try to answer his two main comments briefly here. …

Danzon, P., Wang, M., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from twenty five major markets in the 1990s. Health Eco. 14, 269–295 (2005)CrossRef

Titel: Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
verfasst von: Livio Garattini
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 2/2007
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-007-0056-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Pharmacoeconomic studies in Italy: a critical review of the literature

The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management

Systematic review of economic evaluations and cost analyses of guideline implementation strategies

The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49